Cytiva Aseptic Filling Cell & Gene Tech Expo April 2026: Commercial Readiness

As gene-modified cell therapies move from clinical trials toward commercial scale, the industry is outgrowing traditional fill-finish assumptions. Conventional equipment designed for high-throughput, "blockbuster" biologics often struggles with the unique requirements of modern modalities—specifically the need for rapid processing to preserve cell viability and the flexibility to handle multiple patient-specific batches in a single shift. Transitioning from manual or semi-automated processes to robotic, closed systems is becoming a critical strategy for maintaining GMP compliance while minimizing the risk of human-introduced contamination.

Automation in aseptic filling does more than just increase speed; it fundamentally improves product safety by eliminating direct operator intervention. Utilizing robotic gloveless isolators and single-use flow paths allows for highly precise filling with minimal product loss—a vital factor when handling high-value therapies. These standardized, compact systems can significantly shorten the path to manufacturing readiness, often helping facilities reach a GMP-ready state months faster than custom-built alternatives. Watch the full presentation to explore how these integrated technologies support scalable, repeatable, and safe cell therapy production.

About Cytiva

At Cytiva, we envision a world in which access to life-changing therapies transforms human health. With a rich heritage dating back hundreds of years, our wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery.

Cytiva is proud to be part of Danaher. Danaher is a global life sciences and diagnostics innovator committed to accelerating the power of science and technology to improve human health. Together, we partner with customers to solve their toughest challenges—with speed and certainty.